Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dyskinesia Receiving Long-Term Valbenazine (NBI-98854) Treatment
Objective: To assess the emergence of extrapyramidal symptoms (EPS) such as akathisia and parkinsonism in adults with a diagnosis of schizophrenia/schizoaffective disorder or mood disorder…Drug-induced movement disorders: not a typical problem
Objective: To characterize patients with neuroleptic drug-induced movement disorders (DIMD) referred to a single academic center Movement Disorders clinic, their causative medications and the indications…Long-Term Safety of Deutetrabenazine for the Treatment of Tardive Dyskinesia: Results From an Open-Label, Long-Term Study
Objective: To evaluate the long-term safety/tolerability of deutetrabenazine (DTB) in patients with tardive dyskinesia (TD). Week 54 open-label results are reported in this interim analysis.…Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD and AIM-TD Studies
Objective: To evaluate the efficacy of deutetrabenazine (DTB), as measured by the Clinical Global Impression of Change (CGIC), in patients with tardive dyskinesia (TD) from…Tardive Dyskinesia by Body Region in Subjects with Schizophrenia/Schizoaffective Disorder or Mood Disorder: Findings from the KINECT 3 Study
Objective: To characterize dyskinesia distribution by body region in subjects with tardive dyskinesia (TD) enrolled in a clinical trial of valbenazine, based on baseline Abnormal…Deutetrabenazine Treatment Response by Concomitant Dopamine-Receptor Antagonists in the Phase III, Randomized, Double-Blind, Placebo-Controlled AIM-TD Trial in Tardive Dyskinesia
Objective: To determine the impact of dopamine-receptor antagonist (DRA) use at baseline on the efficacy, safety, and tolerability of deutetrabenazine in patients with tardive dyskinesia…An MCID for AIMS Dyskinesia Total Score Change in Subjects with Tardive Dyskinesia
Objective: To establish a minimal clinically important difference (MCID) for Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score change using data from randomized, double-blind, placebo…Deutetrabenazine is Associated with an Improvement in Involuntary Movements in Patients With Tardive Dyskinesia as Seen by the High Proportion of Responders to Deutetrabenazine Treatment in the AIM-TD Study
Objective: To examine response rates between patients receiving deutetrabenazine and placebo. Response levels were pre-specified from 10–90% improvement from baseline in Abnormal Involuntary Movement Scale…Evaluation of Patient-Reported Outcomes in Tardive Dyskinesia Patients With Underlying Psychotic and Mood Disorders in the ARM-TD and AIM-TD Trials
Objective: To assess patients’ impression of treatment benefit from deutetrabenazine (DTB) for the treatment of tardive dyskinesia (TD). Background: In TD, patients’ perception of benefit…A survey of movement disorders in a large sample of patients treated with antipsychotic medication
Objective: To describe the prevalence and nature of movement disorders (MD) in a large sample of patients treated with antipsychotic medication. Background: Although there are…
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- Next Page »